SYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).

Size: px
Start display at page:

Download "SYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres)."

Transcription

1 Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group, multi-centre, phase III study comparing the efficacy and safety of Symbicort Turbuhaler 160/4.5 µg twice daily and Pulmicort Turbuhaler 200 µg twice daily + Theolong tablet 200 mg twice daily in Japanese patients with asthma Co-ordinating investigator Not applicable Study centre(s) This study was conducted in Japan (57 centres). Publications None at the time of writing this report. Study dates Phase of development First patient enrolled 18 October 2005 Therapeutic confirmatory (III) Last patient completed 06 November 2006 Objectives The primary objective of this study was to confirm the efficacy (superiority) of Symbicort Turbuhaler 160/4.5μg (D.D.: delivered dose) twice daily for 8 weeks in comparison to Pulmicort Turbuhaler 200 µg (M.D.: metered dose) twice daily + Theolong tablet 200 mg twice daily by assessment of the following variables. Primary variable: Change in average morning peak expiratory flow (mpef) from the run-in to the treatment period.

2 Secondary variables: Change from the run-in period to the treatment period in average: Evening peak expiratory flow (epef) Asthma symptom score (daytime, night time and total) Use of short-acting β 2 -agonist (daytime, night time and total) Night time awakenings due to asthma symptoms Symptom free day Asthma control day Change from Visit 2 to the average of Visit 4 and 5: Forced expiratory volume in one second (FEV 1 ) The secondary objective of this study was to assess the safety of Symbicort Turbuhaler 160/4.5μg (D.D.) twice daily for 8 weeks compared with Pulmicort Turbuhaler 200 µg (M.D.) twice daily + Theolong tablet 200 mg twice daily in terms of the following variables. Adverse events (nature, incidence and severity) Haematology, clinical chemistry and urinalysis 12-lead electrocardiogram (ECGs), blood pressure, pulse rate Study design This was a randomised, double-blind, parallel group, multicentre study in Japanese patients with asthma aged 16 years or older. Target patient population and sample size Outpatients aged 16 years or older with asthma whose forced expiratory volume in one second (FEV 1 ) was 50% of predicted normal, and who were treated with inhaled corticosteroid and theophylline SR tablet as a basic asthma treatment. 2

3 Investigational product: dosage, mode of administration and batch numbers Test product Symbicort Turbuhaler 160/4.5μg (D.D.) (dry powder inhaler, budesonide 160 µg and formoterol fumarate dihydrate 4.5 µg/dose, 120 doses/inhaler) (Batch numbers: GE39) Placebo for test product Symbicort Turbuhaler 160/4.5μg (D.D.) placebo (matching Symbicort Turbuhaler 160/4.5μg), dry powder inhaler containing lactose, 120 doses/inhaler) (Batch numbers: GE21) The patient took one inhalation containing the active ingredient or one inhalation from the placebo inhaler twice daily in the treatment period. Comparator Pulmicort Turbuhaler 200 µg (M.D.) (dry powder inhaler, budesonide 200 µg/dose, 112 doses/inhaler) (Batch numbers: GF11) Theolong tablet 200 mg (Batch numbers: 54A10M) Placebo for comparator Pulmicort Turbuhaler 200 µg (M.D.) placebo (matching Pulmicort Turbuhaler, dry powder inhaler containing lactose, 112 doses/inhaler) (Batch numbers: GF11) Theolong tablet 200 mg placebo (matching Theolong tablet 200 mg) (Batch numbers: P56001AZA) The patient took one inhalation and one tablet containing the active ingredient, or one inhalation from the placebo inhaler and one placebo tablet twice daily in the treatment period. Duration of treatment Run-in period: 2 weeks Treatment period: 8 weeks Criteria for evaluation (main variables) Efficacy and pharmacokinetics Primary variable: Change in average morning peak expiratory flow (mpef) from the run-in to the treatment period. 3

4 Secondary variables: Change from the run-in period to the treatment period in average: Evening peak expiratory flow (epef) Asthma symptom score (daytime, night time and total) Use of short-acting β 2 -agonist (daytime, night time and total) Night time awakenings due to asthma symptoms Symptom free day Asthma control day Change from Visit 2 to the average of Visit 4 and 5: Forced expiratory volume in one second (FEV 1 ) Safety Adverse events (nature, incidence and severity) Haematology, clinical chemistry and urinalysis 12-lead electrocardiogram (ECGs), blood pressure, pulse rate Statistical methods The change in average mpef from the run-in period to the treatment period was the primary outcome variable. The period averages were calculated for the last 10 days of the run-in period and for the whole of the treatment period. Comparison between the treatments was performed using an analysis of covariance model (an additive model) including treatment as a fixed factor and the run-in period average as a covariate. The mean treatment difference was estimated from the model, and 95% confidence interval and p-value were calculated. The primary analysis set for efficacy was the Full Analysis Set. Patient population In total, 569 patients were enrolled and 348 patients were randomised to either of the two treatment groups (Symbicort group: n=178, Pulmicort +Theolong group: n=170) at 57 centres. The number of analysed patients was 346 (Symbicort group: n=176, Pulmicort + Theolong group: n=170) in the FAS and safety analysis set. There were few major protocol deviations (i.e. deviation from inclusion and exclusion criteria) and the compliance was generally good in the both treatment groups. The treatment groups were well-balanced with regards to demography and other baseline characteristics. 4

5 Table S 1 Patient population and disposition Symbicort PUL + Theolong Population Number of randomised (Number of planned) 178 (170) 170 (170) Demographic characteristics Race Oriental 178 (100.0%) 170 (100.0%) Sex Male 71 (39.9%) 60 (35.3%) Female 107 (60.1%) 110 (64.7%) Age (years) Mean (SD) 49.7 (16.2) 48.4 (16.6) Range (19 to 80) (17 to 85) Weight (kg) Mean (SD) c 61.2 (11.8) 61.4 (13.6) Range (30 to 94) (42 to 135) Height (cm) Mean (SD) c (9.8) (9.6) Range (143 to 187) (140 to 183) Baseline characteristics Duration of asthma (years) Mean (SD) c (10.19) (11.55) Range (0.3 to 57.4) d (0.3 to 52.2) d mpef (L/min) Mean (SD) c (118.5) (103.5) epef (L/min) Mean (SD) c (118.6) (103.4) FEV 1 (L) Mean (SD) c (0.760) (0.722) FEV 1 % of predicted normal Mean (SD) c 72.5 (13.0) 72.6 (15.5) FEV 1 reversibility % Mean (SD) c 21.8 (12.9) 22.1 (13.0) Asthma symptom score (total) Mean (SD) c (0.824) (0.867) Number of use of short-acting β 2 - Mean (SD) c (1.039) (0.933) agonist (total) Daily dose of inhaled steroid (μg) Mean (SD) c (141.4) (140.7) Daily dose of inhaled steroid Mean (SD) c (192.7) (189.0) (BDP equivalent a ) (μg) Disposition Number (%) of patients who Completed 167 (93.8%) 164 (96.5%) Discontinued 11 (6.2%) 6 (3.5%) Number of patients analysed for safety b Number of patients analysed for efficacy (FAS) Number of patients analysed for efficacy (PPS) PUL: Pulmicort, SD: Standard deviation; FAS: Full Analysis Set; PPS: Per-protocol Set a: BDP equivalent was calculated with reference to JGL b: Number of patients who took at least 1 dose of randomised investigational product and had any safety data after randomisation c: Symbicort group n=177 d: Duration of asthma was calculated based upon consent signed date in this table. All patients had more than 6 months duration of asthma based upon Visit 1. 5

6 Efficacy results The increase in mpef as primary variable was statistically significantly greater in the Symbicort group than in the Pulmicort + Theolong group (p=0.0051: ANCOVA). Regarding secondary variables, the increase in epef was statistically significantly greater in the Symbicort group than in the Pulmicort + Theolong group (p=0.0355: ANCOVA), but there were no statistically significant differences in the change of other secondary variables (asthma symptom score, use of short-acting β 2 -agonist, night time awakenings due to asthma symptoms, symptom free day, asthma control day and FEV 1 ) between treatment groups. Table S 2 Analysis of change from run-in period to whole treatment period in morning PEF (L/min) (FAS) Treatment Estimate SEM 95% CI p-value Lower Upper Symbicort PUL + Theolong Symbicort - [PUL + Theolong] PUL: Pulmicort, SEM: Standard error of the mean, CI: Confidence interval ANCOVA model (an additive model) including treatment as fixed factor, and baseline as a covariate. Table S 3 Analysis of changes from run-in period to whole treatment period between Symbicort and Pulmicort+Theolong in secondary variables Secondary variable Difference of changes (Symbicort - [PUL+Theolong]) Estimate SEM 95% CI p-value Lower Upper Evening PEF (L/min) Asthma symptom score Daytime Night time Total Number of use of short-acting β 2 -agonist Daytime Night time Total % of short-acting β 2 -agonist free days % of night time awakening days % of symptom free days % of asthma control days FEV PUL: Pulmicort, SEM: Standard error of the mean, CI: Confidence interval ANCOVA model (an additive model) including treatment as fixed factor, and baseline as a covariate. 6

7 Safety results Overall, the both treatments were safe and well tolerated. The incidence and nature of AEs were similar between the both treatment groups. Nasopharyngitis and headache were the most common adverse events in both treatment groups. The number of drug-related AEs (all nonserious) was numerically higher in the Symbicort group (Symbicort group: 19 events in 14 patients, Pulmicort + Theolong group: 11 events in 7 patients), mainly caused by reports of class-related AEs for β 2 -agonists, such as headache and muscle spasms. No deaths were reported in the study. The incidence of SAEs was low in the both treatment groups (Symbicort group: 1 event in 1 patient, Pulmicort + Theolong group: 2 events in 1 patient) and there was no SAE that was assessed as causally related to the investigational product. The incidence of DAEs was similar between the two groups (Symbicort group: 6 events in 6 patients, Pulmicort+Theolong group: 5 events in 5 patients). No other significant AEs were identified in this study. There were no findings for clinical laboratory values, vital signs or ECG that gave any reason for concern regarding the safety of either treatment. Table S 4 Number (%) of patients who had at least 1 adverse event in any category, and total numbers of adverse events (safety analysis set) Symbicort PUL + Theolong (n=176) (n=170) n (%) n (%) Number of patients a Any AEs 81 (46.0) 69 (40.6) Serious AEs leading to death 0 0 Serious AEs not leading to death 1 (0.6) 1 (0.6) AEs that caused patients to discontinue the study 6 (3.4) 5 (2.9) Other significant AEs 0 0 Any drug-related AEs b 14 (8.0) 7 (4.1) Total number of recorded events: Any AEs Serious AEs leading to death 0 0 Serious AEs not leading to death 1 2 AEs that caused patients to discontinue the study 6 5 Other significant AEs 0 0 Any drug-related AEs b PUL: Pulmicort a: Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories. b: The causality was judged by the investigator. 7

8 Table S 5 Number (%) of patients with the most commonly reported a adverse events by preferred term (safety analysis set) Preferred term Symbicort PUL + Theolong (n=176) (n=170) n (%) n (%) NASOPHARYNGITIS 17 (9.7) 27 (15.9) HEADACHE 12 (6.8) 5 (2.9) ASTHMA 5 (2.8) 2 (1.2) PHARYNGITIS 4 (2.3) 3 (1.8) BACK PAIN 4 (2.3) 1 (0.6) MUSCLE SPASMS 4 (2.3) 0 UPPER RESPIRATORY TRACT INFECTION 3 (1.7) 2 (1.2) GASTRITIS 3 (1.7) 1 (0.6) DIARRHOEA 3 (1.7) 0 DYSMENORRHOEA 3 (1.7) 0 RASH 3 (1.7) 0 BRONCHITIS ACUTE 2 (1.1) 3 (1.8) CYSTITIS 2 (1.1) 2 (1.2) PHARYNGOLARYNGEAL PAIN 2 (1.1) 2 (1.2) ACUTE TONSILLITIS 2 (1.1) 1 (0.6) CONSTIPATION 2 (1.1) 1 (0.6) DYSPHONIA 2 (1.1) 1 (0.6) RHINITIS ALLERGIC 2 (1.1) 1 (0.6) DRY EYE 2 (1.1) 0 HYPOAESTHESIA 2 (1.1) 0 MYALGIA 2 (1.1) 0 REFLUX OESOPHAGITIS 2 (1.1) 0 NAUSEA 1 (0.6) 3 (1.8) ABDOMINAL PAIN UPPER 1 (0.6) 2 (1.2) STOMATITIS 1 (0.6) 2 (1.2) PYREXIA 0 3 (1.8) ARTHRALGIA 0 2 (1.2) GASTROENTERITIS 0 2 (1.2) INFLUENZA 0 2 (1.2) TOOTHACHE 0 2 (1.2) TREMOR 0 2 (1.2) PUL: Pulmicort a This table uses a cut-off of 1% of patients on PT level in any of the treatment groups 8

9 Conclusion(s) Symbicort Turbuhaler 160/4.5 μg 1 inhalation twice daily was more effective than Pulmicort Turbuhaler 200 μg 1 inhalation twice daily + Theolong 200 mg twice daily regarding effect on morning PEF and evening PEF. No difference in efficacy was demonstrated between these treatments based on other outcome variables. The both treatments were well tolerated in Japanese patient with asthma and no difference in safety was seen between the two treatments. Date of the report 15 March

International co-ordinating investigator Dr Dencho Osmanliev, St Sofia, Pulmonary Dept, 19 D Nestorov Str, Sofia, 1431, Bulgaria.

International co-ordinating investigator Dr Dencho Osmanliev, St Sofia, Pulmonary Dept, 19 D Nestorov Str, Sofia, 1431, Bulgaria. Drug product: SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0681 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0681 Date: 24 Oktober, 2003 (For national

More information

International Co-ordinating investigator None appointed.

International Co-ordinating investigator None appointed. Drug product: Budesonide/formoterol SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0673 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0673 Date: 13 June,

More information

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers). Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,

More information

SYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.

SYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE. Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel

More information

SYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005

SYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005 Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,

More information

SYNOPSIS. Date 15 June 2004

SYNOPSIS. Date 15 June 2004 Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label

More information

SYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004

SYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004 Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled

More information

SYNOPSIS. Study centres This was a multicentre study conducted in 53 centres in Sweden.

SYNOPSIS. Study centres This was a multicentre study conducted in 53 centres in Sweden. Drug product: Symbicort Turbuhaler Drug substance(s): Budesonide/Formoterol Edition No.: 1 Study code: LD-039-0003 Date: 20 May 2005 SYNOPSIS An open, randomized, parallel group, multicentre, phase IIIB

More information

SYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT

SYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase

More information

Individual Study Table Referring to Part of the Dossier. Volume:

Individual Study Table Referring to Part of the Dossier. Volume: Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS

More information

SYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.

SYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites. Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and

More information

SYNOPSIS. A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT

SYNOPSIS. A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT Drug product: RHINOCORT AQUA Drug substance(s): Budesonide Edition No.: Final Study code: D5360C00703 Date: 8 November 2005 SYNOPSIS A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Rapporteur s Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended

Rapporteur s Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Rappteur s Public Assessment Rept f paediatric studies submitted in accdance with Article 45 of Regulation (EC) No1901/2006, as amended Symbict Turbohaler 80/4.5 μg, 160/4.5 μg, 320/9 μg DE/W/046/pdWS/001

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)

Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years

The clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the

More information

SYNOPSIS. Study centre(s) A total of 91 centres across Canada participated in this study.

SYNOPSIS. Study centre(s) A total of 91 centres across Canada participated in this study. Drug product: Symbicort Turbuhaler Drug substance(s): Budesonide/formoterol Edition No.: 1 Date: August 22, 2007 SYNOPSIS A comparison of Symbicort SMART a (Symbicort 200 Turbuhaler 1 inhalation b.i.d.

More information

Principal Investigator. Study center(s) This was a single-center study. Publications None at the time of writing this report.

Principal Investigator. Study center(s) This was a single-center study. Publications None at the time of writing this report. (For national authority SYNOPSIS use only) Date 3 March 2005 An open, randomized, two-way crossover study evaluating the pharmacokinetics of budesonide and formoterol from Symbicort pmdi versus Oxis Turbuhaler

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Secondary Outcome/Efficacy Variable(s):

Secondary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122

Study No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122 Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

mg 25 mg mg 25 mg mg 100 mg 1

mg 25 mg mg 25 mg mg 100 mg 1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Steinmetz K O, Volmer T, Trautmann M, Kielhorn A

Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Steinmetz K O, Volmer T, Trautmann M, Kielhorn A Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Steinmetz K O, Volmer T, Trautmann M, Kielhorn A Record Status This is a critical abstract of an economic evaluation that

More information

SYNOPSIS. Study Coordinator. Study centre(s)

SYNOPSIS. Study Coordinator. Study centre(s) Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,

More information

SUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.

SUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE. i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment

More information

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Lyrica / Pregabalin

More information

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Individual Study Table Referring to Part of the Dossier. Volume: Page:

Individual Study Table Referring to Part of the Dossier. Volume: Page: 2 CLINICAL STUDY SYNOPSIS FINAL REPORT N0. CCD-0402-RS-0002 Title of the study: Evaluation of the 24-hour trough FEV 1 following 7 days of dosing with 2 µg once daily. A multicentre, double-blind, double-dummy,

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

PFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)

PFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. COMPOUND NUMBER: PROTOCOL NO.: A397113 PROTOCOL TITLE:

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

BUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW

BUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers

More information

Clinical Trial Results Summary Study EN3409-BUP-305

Clinical Trial Results Summary Study EN3409-BUP-305 Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin

More information

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended.

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended. Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Bricanyl () DK/W/0017/pdWS/001 Rapporteur: Denmark Finalisation procedure

More information

Type of intervention Treatment. Economic study type Cost-effectiveness analysis.

Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback

More information

PFIZER INC. GENERIC DRUG NAME and/or COMPOUND NUMBER: 5% Spironolactone Cream/ PF

PFIZER INC. GENERIC DRUG NAME and/or COMPOUND NUMBER: 5% Spironolactone Cream/ PF PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.

Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr

More information

23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)

23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)

More information

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Study Center(s): The study was conducted at 39 study sites in Japan.

Study Center(s): The study was conducted at 39 study sites in Japan. SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

SYNOPSIS (PROTOCOL WX17796)

SYNOPSIS (PROTOCOL WX17796) TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced

More information

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with

More information

Soleus 75 (6 ml) 0 (6 ml) 75 (6 ml. Tibialis posterior 75 (6 ml) 0 (6 ml) 75 (6 ml) Total 300 (24 ml) 0 (24 ml) 300 (24 ml) Dose: U (solution volume)

Soleus 75 (6 ml) 0 (6 ml) 75 (6 ml. Tibialis posterior 75 (6 ml) 0 (6 ml) 75 (6 ml) Total 300 (24 ml) 0 (24 ml) 300 (24 ml) Dose: U (solution volume) Study No.: BTX108512 Title: A Multicenter Study to Evaluate the Efficacy and Safety in Patients with Post-Stroke lower Limb Spasticity Receiving a Double-Blind, -Controlled GSK1358820 Treatment Followed

More information

(For National Authority Use Only) Name of Study Drug: to Part of Dossier:

(For National Authority Use Only) Name of Study Drug: to Part of Dossier: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115

More information

fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK

fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD

James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,

More information

SYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:

SYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page: SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

2. SYNOPSIS Name of Sponsor/Company:

2. SYNOPSIS Name of Sponsor/Company: in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,

More information

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study

More information

Clinical Trial Synopsis TL-OPI-525, NCT#

Clinical Trial Synopsis TL-OPI-525, NCT# Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS

More information

Secondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who

Secondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Summary ID# Clinical Study Summary: Study B4Z-MC-LYCL

Summary ID# Clinical Study Summary: Study B4Z-MC-LYCL CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine

More information

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309

More information

Budesonide equivalent dosing

Budesonide equivalent dosing Budesonide equivalent dosing dosage, adverse reactions, pharmacology and more. Budesonide 0.5mg Nebuliser Suspension (Breath Ltd) - Summary of Product Characteristics (SmPC) by Actavis UK Ltd 11-9-2012

More information

Abstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory

Abstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories

More information

Dual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.

Dual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS. DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

AUSTRALIAN PRODUCT INFORMATION. SYMBICORT TURBUHALER (budesonide/formoterol (eformoterol) fumarate dihydrate)

AUSTRALIAN PRODUCT INFORMATION. SYMBICORT TURBUHALER (budesonide/formoterol (eformoterol) fumarate dihydrate) AUSTRALIAN PRODUCT INFORMATION SYMBICORT TURBUHALER (budesonide/formoterol (eformoterol) fumarate dihydrate) 1 NAME OF THE MEDICINE Budesonide Eformoterol fumarate dihydrate is now known as formoterol

More information

Sponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates.

Sponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates. Sponsor Novartis Generic drug name Fluticasone propionate Trial indication(s) Moderate-severe bronchial asthma Protocol number CQAE397A2202 Protocol title A randomized open label study to assess the utility

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Summary ID# Clinical Study Summary: Study B4Z-JE-LYBC

Summary ID# Clinical Study Summary: Study B4Z-JE-LYBC CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride

More information

Clinical Trial Synopsis

Clinical Trial Synopsis Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name

More information

T he use of inhaled corticosteroids to control the inflammatory

T he use of inhaled corticosteroids to control the inflammatory 791 ORIGINAL ARTICLE Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose D Price, D Dutchman, A Mawson, B Bodalia, S Duggan, P Todd on behalf of the

More information

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301 SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations

More information

Title of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Title of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy

More information